121 related articles for article (PubMed ID: 15943897)
1. A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
Jones SF; Kuhn JG; Greco FA; Raefsky EL; Hainsworth JD; Dickson NR; Thompson DS; Willcutt NT; White MB; Burris HA
Clin Lung Cancer; 2005 May; 6(6):361-6. PubMed ID: 15943897
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).
Masters GA; Li S; Dowlati A; Madajewicz S; Langer C; Schiller J; Johnson D
J Thorac Oncol; 2006 Sep; 1(7):673-8. PubMed ID: 17409935
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Weiss GJ; Vokes EE; Bunn PA; Magree L; Rusk J; Albert D; Kelly K
J Thorac Oncol; 2007 Oct; 2(10):933-8. PubMed ID: 17909356
[TBL] [Abstract][Full Text] [Related]
5. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
[TBL] [Abstract][Full Text] [Related]
6. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
Bunn PA; Chan DC; Earle K; Zhao TL; Helfrich B; Kelly K; Piazza G; Whitehead CM; Pamukcu R; Thompson W; Alila H
Semin Oncol; 2002 Feb; 29(1 Suppl 4):87-94. PubMed ID: 11894018
[TBL] [Abstract][Full Text] [Related]
8. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
Whitehead CM; Earle KA; Fetter J; Xu S; Hartman T; Chan DC; Zhao TL; Piazza G; Klein-Szanto AJ; Pamukcu R; Alila H; Bunn PA; Thompson WJ
Mol Cancer Ther; 2003 May; 2(5):479-88. PubMed ID: 12748310
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
Govindan R; Wang X; Baggstrom MQ; Burdette-Radoux S; Hodgson L; Vokes EE; Green MR;
J Thorac Oncol; 2009 Feb; 4(2):220-6. PubMed ID: 19179900
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of the docetaxel-carboplatin chemotherapy regimen in advanced non-small-cell lung cancer.
Tsavaris N; Kosmas C; Skopelitis E; Gennatas K; Zorbala A; Papas P; Gouveris P; Antypas G; Rokana S; Tzelepis G
Lung; 2005; 183(6):405-16. PubMed ID: 16465600
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer.
Kataoka K; Suzuki R; Taniguchi H; Noda Y; Shindoh J; Matsumoto S; Watanabe Y; Honda K; Suzuki K; Baba K; Imaizumi K; Kume H; Hasegawa Y; Takagi K
Lung; 2006; 184(3):133-9. PubMed ID: 16902837
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.
Ramalingam S; Dobbs TW; Einzig AI; Wojtowicz-Praga S; Cascino M; Bonomi P; Belani CP
Cancer Chemother Pharmacol; 2004 May; 53(5):439-44. PubMed ID: 15132135
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
Hoang T; Kim K; Merchant J; Traynor AM; McGovern J; Oettel KR; Sanchez FA; Ahuja HG; Hensing TA; Larson M; Schiller JH
J Thorac Oncol; 2006 Mar; 1(3):218-25. PubMed ID: 17409860
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
Giannakakis T; Kakolyris S; Theodoropoulos E; Kouroussis C; Michailakis E; Papadouris S; Tsitoura M; Kalbakis K; Souglakos J; Agelaki S; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(6B):3743-8. PubMed ID: 12552987
[TBL] [Abstract][Full Text] [Related]
20. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
